Clinical economics in clinical trials: The measurement of cost and outcomes in the assessment of clinical services through clinical trials

Keio Journal of Medicine

Volumn 48, Issue 1, 1999, Pages 1-11

  Schulman, Kevin A ^a   Ohishi, Akira ^a,e   Park, Jaewon ^b   Glick, Henry A ^c   Eisenberg, John M ^d  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b National Tokyo Hospital   (Japan)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^e National Hospital Organization Kasumigaura Medical Center   (Japan)

Author keywords

Clinical economics; Clinical trials; Cost effectiveness analysis; Pharmacoeconomics

Indexed keywords

CLINICAL TRIAL; COST; ECONOMICS; HUMAN; JAPAN; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; COSTS AND COST ANALYSIS; HUMANS; JAPAN; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE);

EID: 0033094301     PISSN: 00229717     EISSN: None     Source Type: Journal    
DOI: 10.2302/kjm.48.1     Document Type: Review

References (53)

1. The face of the future in Japan - Economic Threat of Aging Populace. New York Times, September 2, 1997: D1
2. Health and Welfare Statistics Association: Annual change in national health care costs in Japan. Health Welfare Stat 1996; 43(16): 15-25 (in Japanese)
3. Russell LB, Siegel JE, Daniels N, Gold MR, Luce BR, Mandelblatt JS: Cost-effectiveness analysis as a guide to resource allocation in health: roles and limitations. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds, Cost-effectiveness in Health and Medicine, New York, Oxford University Press, 1996; 3-24
4. Ikeda S, Ikegami N, Oliver AJ, Ikeda M: A case for the adoption of pharmacoeconomic guidelines in Japan. Pharmaco Economics 1996; 10: 546-551
5. Schulman KA, Glick H, Buxton M, Sculpher M, Backhouse M, Bell L, Eisenberg JM: The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Control Clin Trials 1996; 17: 304-315
6. Bombardier C, Eisenberg J: Looking into the crystal ball: can we estimate the lifetime cost of rheumatoid arthritis? J Rheumatol 1985; 12: 201-204
7. Drummond MF, O'Brien B, Stoddart GL, Torrance GW, eds: Basic types of economic evaluation. Methods for the Economic Evaluation of Health Care Programs. 2nd Ed, New York, Oxford University Press, 1997; 6-26
8. Schulman KA, Glick HA, Yabroff KR, Eisenberg JM: Introduction to clinical economics: assessment of cancer therapies. Monogr Natl Cancer Inst 1995; 19: 1-9
9. Arrow KJ, Cropper ML, Eads GC, Hahn RW, Lave LB, Noll RG, Portney PR, Russell M, Schmalensee R, Smith VK, Stavins RN: Is there a role for benefit-cost analysis in environmental, health, and safety regulation? Science 1996; 272: 221-222
10. Eisenberg JM: Clinical economics. A guide to economic analysis of clnical practices. JAMA 1989; 262: 2879-2886
11. Okubo I, Glick H, Frumkin H, Eisenberg JM: Cost-effectiveness analysis of mass screening for breast cancer in Japan. Cancer 1991; 67: 2021-2029
12. Shimbo T, Glick HA, Eisenberg JM: Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Assess Health Care 1994; 10: 359-375
13. Lee TH, Fukui T, Weinstein MC, Tosteson AN, Goldman L: Cost-effectiveness of screening strategies for left main coronary artery disease in patients with stable angina. Med Decis Making 1988; 8: 268-278
14. Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR: Cost effectiveness of interferon-α and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996; 125: 541-548
15. Weinstein MC, Stason WB: Cost-effectiveness of coronary artery bypass surgery. Circulation 1982; 66: III56-III66
16. Willems JS, Sanders CR, Riddiough MA, Bell JC: Costeffectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980; 303: 553-559
17. Schulman KA, Kinosian B, Jacobson TA, Glick H, Willian MK, Koffer H, Eisenberg JM: Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. JAMA 1990; 264: 3025-3033
18. Schulman KA, Glick HA, Rubin H, Eisenberg JM: Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent. JAMA 1991; 266: 3466-3471
19. Churchill DN, Lemon BC, Torrance GW: A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis. Med Decis Making 1984; 4: 489-500
20. Torrance GW: Utility approach to measuring health-related quality of life. J Chronic Dis 1987; 40: 593-603
21. Williams A: The importance of quality of life in policy decisions. In: Walker SR, Rosser RM, eds, Quality of Life: Assessment and Application, Lancaster, MTP Press Ltd, 1988; 279-290
22. Torrance GW: Preferences for health states: a review of measurement methods. Mead Johnson Symp Perinat Dev Med 1982; 20: 37-45
23. Gold MR, Patrick DI, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, Daniels N, Weinstein MC: Identifying and valuing outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds, Cost-effectiveness in Health and Medicine, New York, Oxford University Press, 1996; 82-134
24. Eisenberg JM, Kitz DS: Savings from outpatient antibiotic therapy for osteomyelitis. Economic analysis of a therapeutic strategy. JAMA 1986; 255: 1584-1588
25. Nicholson W: Intermediate Microeconomics and Its Application, 6th Ed, Fortworth, Dryden, 1994; 226-260
26. Eisenberg JM, Koffer H, Finkler SA: Economic analysis of a new drug: potential savings in hospital operating costs from the use of a once-daily regimen of a parenteral cephalosporin. Rev Infect Dis 1984; 6: S909-S923
27. Finkler SA: The distinction between cost and charges. Ann Intern Med 1982; 96: 102-109
28. Bridges JM, Jacobs P: Obtaining estimates of marginal cost by DRG. Healthc Financ Manage 1986; 40-46
29. Hsiao WC, Braun P, Dunn DL, Becker ER, Yntema D, Verrilli DK, Stamenovic E, Chen SP: An overview of the development and refinement of the Resource-Based Relative Value Scale. The foundation for reform of U.S. physician payment. Med Care 1992; 30: NS1-NS12
30. Grannemann TW, Brown RS, Pauly MV: Estimating hospital costs, J Health Econ 1986; 5: 107-127
31. Luce BR, Manning WG, Siegel JE, Lipscomb J: Estimating costs in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine, New York, Oxford University Press, 1996; 176-213
32. Landefeld JS, Seskin EP: The economic value of life: linking theory to practice. Am J Public Health 1982; 72: 555-566
33. Rice DP, Hodgson TA: The value of human life revisited. Am J Public Health 1982; 72: 536-538
34. Thompson MS, Read JL, Liang M: Feasibility of willingness-topay measurement in chronic arthritis. Med Decis Making 1984; 4: 195-215
35. Mishan EJ: Cost-benefit Analysis, 3rd Ed, London, George Allen & Unwin, 1992
36. Shelling TC, Chase SB: The life you save may be your own. In Problems in Public Expenditure Analysis, Washington D.C., The Brookings Institution, 1968
37. Eisenberg JM, Schulman KA, Glick H, Koffer H: Pharmacoeconomics: economic evaluation of pharmaceuticalsx In: Strom BL, ed, Pharmacoepidemiology, Chichester, Wiley, 1994; 469-93
38. Schulman KA, Linas BP: Pharmacoeconomics: state of the art in 1997. Annu Rev Public Health 1997; 18: 529-548
39. Drummond M: Economic analysis alongside clinical trials: problems and potential. J Rheumatol 1995; 22: 1403-1407
40. Gulati SC, Bitran JD: Cost-effectiveness analysis: sleeping with an enemy or a friend? J Clin Oncol 1995; 13: 2152-2154
41. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstron PW, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE Jr, Simes J, Topol EJ: Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-1424
42. Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-481
43. Evans D, Freund D, Dittus R, Robertson J, Henry D: The Use of Economic Analysis as a Basis for Inclusion of Pharmacoeconomical Products on the Pharmaceutical Benefits Scheme. Department of Health, Housing and Community Services, Canberra, Commonwealth of Australia, 1990
44. Fayers PM, Hand DJ: Generalisation from phase III clinical trials: survival, quality of life, and health economics. Lancet 1997; 350: 1025-1027
45. Sackett DL, Haynes RB, Guyatt CH, Tugwell P: Clinical Epidemiology: A Basic Science for Clinical Medicine, Boston, Little Brown, 1991
46. Schulman KA, Llana T, Yabroff KR: Economic assessment within the clinical development program. Med Care 1996; 34: DS89-DS95
47. O'Brien BJ, Drummond MF, Labelle RJ, Willan A: In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32: 150-163
48. Stiller CA: Centralised treatment, entry to trials and survival. Br J Cancer 1994; 70: 352-362
49. Stiller CA: Survival of patients with cancer. BMJ 1989; 299: 1058-1059
50. Schulman KA, Buxton M, Glick H, Sculpher M, Guzman G, Kong J, Backhouse M, Mauskopf J, Bell L, Eisenberg JM: Results of the economic evaluation of the first study. A multinational prospective economic evaluation. Int J Technol Assess Health Care 1996; 12: 698-713
51. Schulman KA, Dorsainvil D, Yabroff KR, DiCesare J, Felser J, Eisenberg JM, Glick HA, the IL-3 BMT Study Team: Prospective economic evaluation accompanying a trial of GM-CSF/ IL-3 in patients undergoing autologous bone-marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 607-614
52. Hays RD, Sherbourne CD, Bozzette SA: Pharmacoeconomics and quality of life research beyond the randomized clinical trial. In: Spilker B, ed, Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd Ed, Philadelphia, Lippincott-Raven, 1996; 155-159
53. Cunningham WE, Bozzette SA, Hays RD, Kanouse DE, Shapiro MF: Comparison of health-related quality of life in clinical trial and nonclinical trial human immunodeficiency virus cohorts. Med Care 1995; 33: AS15-AS25